home / About us / Research Store / Latest reports / Services / NEWS & MEDIA / contact us

Reports

Ideas That Generate Results

Reports by Industry
Reports by Company
T-Cell Immunotherapy for Cancer - Pipeline Analysis

T-Cell Immunotherapy for Cancer - Pipeline Analysis

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Aug, 2016| No. of Pages : 110

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1800.00
CD-ROM Mail Delivery
US$ 1900.00
Hard Copy Mail Delivery
US$ 1900.00
Electronic Access - Multi-User License
US$ 2500.00
1. Analyst View 
 
2. Research Methodology
 
3. Introduction
 
4. Market Dynamics
    4.1 Market Drivers
            4.1.1 Increasing Number of Investments and Grants
           4.1.2 Technological Advancements
           4.1.3 Robust and Opportunistic Pipeline
           4.1.4 Collaboration amongst Industry Players and Non-Industry Participants
           4.1.5 Rising Research Related Activities
           4.1.6 Venture Capitalist Funding
    4.2 Challenges
           4.2.1 Manufacturing and Regulatory Challenges
          4.2.2 High Cost of Manufacturing Coupled With Demand for Scalability
          4.2.3 Limited Validation of CAR-T Therapy Outside CD19+ Hematological Malignancies 
    4.3 Opportunities
           4.3.1 Juno Therapeutics, Kite Pharma, Novartis Offering Great Opportunities
           4.3.2 CAR-T Therapies Likely to Gain Momentum in Near Future
 
5. Major Therapeutic Areas for T-Cell Therapies
     5.1 Hematological Malignancies
            5.1.1 Leukemia
            5.1.2 Lymphoma
            5.1.3 Multiple Myeloma
     5.2 Solid Tumors
            5.2.1 Melanoma
            5.2.2 Bladder Cancer
            5.2.3 Kidney Cancer
            5.2.4 Ovarian Cancer
            5.2.5 Breast Cancer
            5.2.6 Lung Cancer 45
 
6. Pipeline Analysis
 
7. Investments in T-Cell Immunotherapy
 
8. Key Player Analysis
    8.1 Adaptimmune Therapeutics plc
    8.2 Juno Therapeutics, Inc.
    8.3 Kite Pharma, Inc.
    8.4 Novartis International AG 
    8.5 Tessa Therapeutics Pte Ltd.
    8.6 Gradalis, Inc.
    8.7 Immunovative Therapies, Ltd.
    8.8 Lion Biotechnologies, Inc.
    8.9 Atara Biotherapeutics, Inc.
    8.10 Celgene Corporation
    8.11 Cellular Biomedicine Group
    8.12 GlaxoSmithKline plc.
    8.13 Immunocore Ltd.
    8.14 Inovio Pharmaceuticals, Inc.
    8.15 Cell Medica
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.

Not readable? Change text.